Pinkmartini的个人主页 - 老虎社区

Pinkmartini

Pinkmartini

A solo and freestyle trader

IP属地：未知

169关注

3粉丝

0主题

0勋章

2021-10-20

Heard that this was old news by Politico, causing the dip of the shares.

Novavax plunged over 20% in premarket trading

2021-07-02

Always read more details and find out the companies that you are buying before you stuck with all these stocks.

After-Hours Stock Movers:BioSig,Cerence,Adtalem Global Education and more

2021-07-09

👍 nice

Chinese battery maker EVE to invest in lithium production

2021-09-21

😭gloomy day

Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week

2021-09-14

$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.

2021-07-30

Hoping it will go higher😁

Exxon posts highest profit in more than a year

2021-07-14

$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound

2021-06-26

Yes APPLE is definitely a better buy😉

Is Apple A Better Buy Than Other FAANG Stocks?

2021-06-26

It is kinda high now to buy in ~

Tesla Stock Has Been on Fire This Week. Here Are 4 Reasons.

2021-10-25

👍

Toplines Before US Market Open on Monday

2021-08-04

Nice

抱歉，原内容已删除

2021-06-30

I don’t think it would crash. Depending which angle you are looking at .

2 Robinhood Stocks That Could Crush Dogecoin

2021-06-26

Too high

抱歉，原内容已删除

2021-07-08

Finally it soar again after a few months of low

2021-07-02

The future travel

Branson aims to make space trip on July 11, ahead of Bezos

2021-06-28

😆

抱歉，原内容已删除

2021-06-28

It is another volatile stocks with high returns

Virgin Galactic stock surged another 8% in premarket trading

2021-11-24

Tell me your opinion about this news...

Chamath Palihapitiya says he will increase stake in Clover Health

2021-08-12

Impressive 😄

Clover Health shares rose nearly 12% in premarket trading.

2021-07-26

Yea it will go higher

@小虎AV:Krish Sankar, senior research analyst at Cowen, joined "Squawk Box" to discuss his outperform rating and $180 price target on Apple's stock.$Apple(AAPL)$

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3585729847029660","uuid":"3585729847029660","gmtCreate":1622795342156,"gmtModify":1634652902800,"name":"Pinkmartini","pinyin":"pinkmartini","introduction":"","introductionEn":"","signature":"A solo and freestyle trader","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":169,"tweetSize":31,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":875712367,"gmtCreate":1637686423087,"gmtModify":1637686423087,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875712367","repostId":"1113618972","repostType":2,"repost":{"id":"1113618972","pubTimestamp":1637282847,"share":"https://www.laohu8.com/m/news/1113618972?lang=&edition=full","pubTime":"2021-11-19 08:47","market":"us","language":"en","title":"Chamath Palihapitiya says he will increase stake in Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1113618972","media":"seekingalpha","summary":"Social Capital CEO Chamath Palihapitiya said that the venture capital firm will increase its investm","content":"<p>Social Capital CEO Chamath&nbsp;Palihapitiya said that the venture capital firm will increase its investment in Clover Health Investments(NASDAQ:CLOV), according to a&nbsp;market observations letter&nbsp;he posted on his Twitter page.</p>\n<p>He cited life sciences, climate science, and alternate finance as areas \"ripe for opportunity.\"</p>\n<p>To build cash reserves and fund new investments, he is&nbsp;selling 15% of the firm's stake in SoFi Technologies(NASDAQ:SOFI).</p>\n<p>He is buying into Mitra Chem, Spectral, and Syndica.</p>\n<p>Last night, Clover Health priced a$300M public offering of common shares.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chamath Palihapitiya says he will increase stake in Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChamath Palihapitiya says he will increase stake in Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-19 08:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3772693-chamath-palihapitiya-he-will-increase-stake-in-clover-health><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Social Capital CEO Chamath Palihapitiya said that the venture capital firm will increase its investment in Clover Health Investments(NASDAQ:CLOV), according to a market observations letter he posted ...</p>\n\n<a href=\"https://seekingalpha.com/news/3772693-chamath-palihapitiya-he-will-increase-stake-in-clover-health\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://seekingalpha.com/news/3772693-chamath-palihapitiya-he-will-increase-stake-in-clover-health","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1113618972","content_text":"Social Capital CEO Chamath Palihapitiya said that the venture capital firm will increase its investment in Clover Health Investments(NASDAQ:CLOV), according to a market observations letter he posted on his Twitter page.\nHe cited life sciences, climate science, and alternate finance as areas \"ripe for opportunity.\"\nTo build cash reserves and fund new investments, he is selling 15% of the firm's stake in SoFi Technologies(NASDAQ:SOFI).\nHe is buying into Mitra Chem, Spectral, and Syndica.\nLast night, Clover Health priced a$300M public offering of common shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844014029,"gmtCreate":1636377122334,"gmtModify":1636377123305,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844014029","repostId":"1137044759","repostType":4,"repost":{"id":"1137044759","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635163753,"share":"https://www.laohu8.com/m/news/1137044759?lang=&edition=full","pubTime":"2021-10-25 20:09","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1137044759","media":"Tiger Newspress","summary":"U.S. futures rose slightly on Monday as traders geared for a string of earnings reports from technol","content":"<p>U.S. futures&nbsp;rose slightly&nbsp;on Monday as traders geared for a string of earnings reports from technology heavyweights including <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc., while keeping in mind inflation concerns and rising Covid-19 risks.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up&nbsp;3&nbsp;points, or 0.01%, S&amp;P 500 e-minis were up&nbsp;5.75&nbsp;points, or 0.13%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis were&nbsp;up&nbsp;44.25&nbsp;points, or 0.29%.<img src=\"https://static.tigerbbs.com/92e0a1d5cd73c51f28ccb00c8d4f071c\" tg-width=\"553\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> (PINS) – Pinterest shares tumbled 13.2% in premarket trading after&nbsp;PayPal said it was&nbsp;not pursuing an acquisition&nbsp;of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> shares jumped 6.1%.</p>\n<p><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a> (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but <a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a>’s results were hit by higher inflation and supply chain issues.</p>\n<p><a href=\"https://laohu8.com/S/QSR\">Restaurant</a> (QSR) – The restaurant operator&nbsp;reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/OTIS\">Otis Worldwide Corp</a> (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.</p>\n<p><a href=\"https://laohu8.com/S/FB\">Facebook</a> (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KNX\">Knight Transportation</a> (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.</p>\n<p><a href=\"https://laohu8.com/S/HSBC\">HSBC Holdings PLC</a> (HSBC) – HSBC&nbsp;reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.</p>\n<p><a href=\"https://laohu8.com/S/SWX\">Southwest Gas</a> (SWX) – Investor Carl Icahn is calling on <a href=\"https://laohu8.com/S/OKSB\">Southwest</a> Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company <a href=\"https://laohu8.com/S/STR\">Questar</a>. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.</p>\n<p><a href=\"https://laohu8.com/S/WHR\">Whirlpool</a> (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE),<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-25 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. futures&nbsp;rose slightly&nbsp;on Monday as traders geared for a string of earnings reports from technology heavyweights including <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc., while keeping in mind inflation concerns and rising Covid-19 risks.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up&nbsp;3&nbsp;points, or 0.01%, S&amp;P 500 e-minis were up&nbsp;5.75&nbsp;points, or 0.13%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis were&nbsp;up&nbsp;44.25&nbsp;points, or 0.29%.<img src=\"https://static.tigerbbs.com/92e0a1d5cd73c51f28ccb00c8d4f071c\" tg-width=\"553\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> (PINS) – Pinterest shares tumbled 13.2% in premarket trading after&nbsp;PayPal said it was&nbsp;not pursuing an acquisition&nbsp;of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> shares jumped 6.1%.</p>\n<p><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a> (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but <a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a>’s results were hit by higher inflation and supply chain issues.</p>\n<p><a href=\"https://laohu8.com/S/QSR\">Restaurant</a> (QSR) – The restaurant operator&nbsp;reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/OTIS\">Otis Worldwide Corp</a> (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.</p>\n<p><a href=\"https://laohu8.com/S/FB\">Facebook</a> (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KNX\">Knight Transportation</a> (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.</p>\n<p><a href=\"https://laohu8.com/S/HSBC\">HSBC Holdings PLC</a> (HSBC) – HSBC&nbsp;reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.</p>\n<p><a href=\"https://laohu8.com/S/SWX\">Southwest Gas</a> (SWX) – Investor Carl Icahn is calling on <a href=\"https://laohu8.com/S/OKSB\">Southwest</a> Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company <a href=\"https://laohu8.com/S/STR\">Questar</a>. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.</p>\n<p><a href=\"https://laohu8.com/S/WHR\">Whirlpool</a> (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE),<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QSR":"餐饮品牌国际","PINS":"Pinterest, Inc.","SWX":"Southwest Gas Corp","WHR":"惠而浦",".DJI":"道琼斯","TSLA":"特斯拉","KNX":"Knight Transportation Inc","BNTX":"BioNTech SE","OTIS":"奥的斯","PFE":"辉瑞","HSBC":"汇丰","KMB":"金佰利"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137044759","content_text":"U.S. futures rose slightly on Monday as traders geared for a string of earnings reports from technology heavyweights including Facebook Inc., while keeping in mind inflation concerns and rising Covid-19 risks.\nAt 8:00 a.m. ET, Dow e-minis were up 3 points, or 0.01%, S&P 500 e-minis were up 5.75 points, or 0.13%, and Nasdaq 100 e-minis were up 44.25 points, or 0.29%.Stocks making the biggest moves in the premarket:\nPinterest, Inc. (PINS) – Pinterest shares tumbled 13.2% in premarket trading after PayPal said it was not pursuing an acquisition of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. PayPal shares jumped 6.1%.\nTesla Motors (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.\nKimberly-Clark (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but Kimberly-Clark’s results were hit by higher inflation and supply chain issues.\nRestaurant (QSR) – The restaurant operator reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.\nOtis Worldwide Corp (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.\nFacebook (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.\nKnight Transportation (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.\nHSBC Holdings PLC (HSBC) – HSBC reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.\nSouthwest Gas (SWX) – Investor Carl Icahn is calling on Southwest Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company Questar. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.\nWhirlpool (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.\nPfizer (PFE),BioNTech SE (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.","news_type":1},"isVote":1,"tweetType":1,"viewCount":761,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856808141,"gmtCreate":1635166163293,"gmtModify":1635166163416,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856808141","repostId":"1137044759","repostType":4,"repost":{"id":"1137044759","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635163753,"share":"https://www.laohu8.com/m/news/1137044759?lang=&edition=full","pubTime":"2021-10-25 20:09","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1137044759","media":"Tiger Newspress","summary":"U.S. futures rose slightly on Monday as traders geared for a string of earnings reports from technol","content":"<p>U.S. futures&nbsp;rose slightly&nbsp;on Monday as traders geared for a string of earnings reports from technology heavyweights including <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc., while keeping in mind inflation concerns and rising Covid-19 risks.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up&nbsp;3&nbsp;points, or 0.01%, S&amp;P 500 e-minis were up&nbsp;5.75&nbsp;points, or 0.13%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis were&nbsp;up&nbsp;44.25&nbsp;points, or 0.29%.<img src=\"https://static.tigerbbs.com/92e0a1d5cd73c51f28ccb00c8d4f071c\" tg-width=\"553\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> (PINS) – Pinterest shares tumbled 13.2% in premarket trading after&nbsp;PayPal said it was&nbsp;not pursuing an acquisition&nbsp;of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> shares jumped 6.1%.</p>\n<p><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a> (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but <a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a>’s results were hit by higher inflation and supply chain issues.</p>\n<p><a href=\"https://laohu8.com/S/QSR\">Restaurant</a> (QSR) – The restaurant operator&nbsp;reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/OTIS\">Otis Worldwide Corp</a> (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.</p>\n<p><a href=\"https://laohu8.com/S/FB\">Facebook</a> (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KNX\">Knight Transportation</a> (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.</p>\n<p><a href=\"https://laohu8.com/S/HSBC\">HSBC Holdings PLC</a> (HSBC) – HSBC&nbsp;reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.</p>\n<p><a href=\"https://laohu8.com/S/SWX\">Southwest Gas</a> (SWX) – Investor Carl Icahn is calling on <a href=\"https://laohu8.com/S/OKSB\">Southwest</a> Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company <a href=\"https://laohu8.com/S/STR\">Questar</a>. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.</p>\n<p><a href=\"https://laohu8.com/S/WHR\">Whirlpool</a> (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE),<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-25 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. futures&nbsp;rose slightly&nbsp;on Monday as traders geared for a string of earnings reports from technology heavyweights including <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc., while keeping in mind inflation concerns and rising Covid-19 risks.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up&nbsp;3&nbsp;points, or 0.01%, S&amp;P 500 e-minis were up&nbsp;5.75&nbsp;points, or 0.13%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis were&nbsp;up&nbsp;44.25&nbsp;points, or 0.29%.<img src=\"https://static.tigerbbs.com/92e0a1d5cd73c51f28ccb00c8d4f071c\" tg-width=\"553\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> (PINS) – Pinterest shares tumbled 13.2% in premarket trading after&nbsp;PayPal said it was&nbsp;not pursuing an acquisition&nbsp;of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> shares jumped 6.1%.</p>\n<p><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a> (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but <a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a>’s results were hit by higher inflation and supply chain issues.</p>\n<p><a href=\"https://laohu8.com/S/QSR\">Restaurant</a> (QSR) – The restaurant operator&nbsp;reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/OTIS\">Otis Worldwide Corp</a> (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.</p>\n<p><a href=\"https://laohu8.com/S/FB\">Facebook</a> (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KNX\">Knight Transportation</a> (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.</p>\n<p><a href=\"https://laohu8.com/S/HSBC\">HSBC Holdings PLC</a> (HSBC) – HSBC&nbsp;reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.</p>\n<p><a href=\"https://laohu8.com/S/SWX\">Southwest Gas</a> (SWX) – Investor Carl Icahn is calling on <a href=\"https://laohu8.com/S/OKSB\">Southwest</a> Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company <a href=\"https://laohu8.com/S/STR\">Questar</a>. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.</p>\n<p><a href=\"https://laohu8.com/S/WHR\">Whirlpool</a> (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE),<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QSR":"餐饮品牌国际","PINS":"Pinterest, Inc.","SWX":"Southwest Gas Corp","WHR":"惠而浦",".DJI":"道琼斯","TSLA":"特斯拉","KNX":"Knight Transportation Inc","BNTX":"BioNTech SE","OTIS":"奥的斯","PFE":"辉瑞","HSBC":"汇丰","KMB":"金佰利"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137044759","content_text":"U.S. futures rose slightly on Monday as traders geared for a string of earnings reports from technology heavyweights including Facebook Inc., while keeping in mind inflation concerns and rising Covid-19 risks.\nAt 8:00 a.m. ET, Dow e-minis were up 3 points, or 0.01%, S&P 500 e-minis were up 5.75 points, or 0.13%, and Nasdaq 100 e-minis were up 44.25 points, or 0.29%.Stocks making the biggest moves in the premarket:\nPinterest, Inc. (PINS) – Pinterest shares tumbled 13.2% in premarket trading after PayPal said it was not pursuing an acquisition of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. PayPal shares jumped 6.1%.\nTesla Motors (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.\nKimberly-Clark (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but Kimberly-Clark’s results were hit by higher inflation and supply chain issues.\nRestaurant (QSR) – The restaurant operator reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.\nOtis Worldwide Corp (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.\nFacebook (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.\nKnight Transportation (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.\nHSBC Holdings PLC (HSBC) – HSBC reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.\nSouthwest Gas (SWX) – Investor Carl Icahn is calling on Southwest Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company Questar. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.\nWhirlpool (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.\nPfizer (PFE),BioNTech SE (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.","news_type":1},"isVote":1,"tweetType":1,"viewCount":684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856801556,"gmtCreate":1635166123276,"gmtModify":1635166123394,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856801556","repostId":"851921142","repostType":1,"repost":{"id":851921142,"gmtCreate":1634865151633,"gmtModify":1635053291354,"author":{"id":"3583318222987864","authorId":"3583318222987864","name":"TheMilkyWay","avatar":"https://static.tigerbbs.com/190d59bcbcc876e15543cbd430d8c1f2","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583318222987864","idStr":"3583318222987864"},"themes":[],"htmlText":"Here’s why the <a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Covid 19 pill WILLNOT make the <a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines&nbsp;in Sep/ Oct 2021.&nbsp;While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food &amp; Drug Administration (FDA) for its Covid 19 vaccine &amp; the company’s&nbsp;stock price went through some wild fluctuations, there was no plunge","listText":"Here’s why the <a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Covid 19 pill WILLNOT make the <a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines&nbsp;in Sep/ Oct 2021.&nbsp;While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food &amp; Drug Administration (FDA) for its Covid 19 vaccine &amp; the company’s&nbsp;stock price went through some wild fluctuations, there was no plunge","text":"Here’s why the $Merck(MRK)$Covid 19 pill WILLNOT make the $Novavax(NVAX)$Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines in Sep/ Oct 2021. While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its Covid 19 vaccine & the company’s stock price went through some wild fluctuations, there was no plunge","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851921142","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":873,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859408655,"gmtCreate":1634718204697,"gmtModify":1634718404868,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","listText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","text":"Heard that this was old news by Politico, causing the dip of the shares.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859408655","repostId":"1174375951","repostType":4,"repost":{"id":"1174375951","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":860844688,"gmtCreate":1632156617744,"gmtModify":1632802435367,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"😭gloomy day","listText":"😭gloomy day","text":"😭gloomy day","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860844688","repostId":"1194891884","repostType":4,"repost":{"id":"1194891884","pubTimestamp":1632091615,"share":"https://www.laohu8.com/m/news/1194891884?lang=&edition=full","pubTime":"2021-09-20 06:46","market":"us","language":"en","title":"Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1194891884","media":"Barrons","summary":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also","content":"<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p>\n<p>Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p>\n<p>The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p>\n<p>Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p>\n<p><b>Monday 9/20</b></p>\n<p>Lennar reports third-quarter fiscal-2021 results.</p>\n<p>Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p>\n<p><b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p>\n<p><b>Tuesday 9/21</b></p>\n<p>Adobe, AutoZone, and FedEx release earnings.</p>\n<p>Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p>\n<p><b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p>\n<p><b>Wednesday 9/22</b></p>\n<p><b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p>\n<p>General Mills reports first-quarter fiscal-2022 results.</p>\n<p>Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p>\n<p><b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p>\n<p><b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p>\n<p><b>Thursday 9/23</b></p>\n<p>Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p>\n<p>Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p>\n<p><b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p>\n<p><b>Friday 9/24</b></p>\n<p>Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 06:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.\n...</p>\n\n<a href=\"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","CRM":"赛富时",".DJI":"道琼斯",".SPX":"S&P 500 Index","FDX":"联邦快递",".IXIC":"NASDAQ Composite","COST":"好市多","ADBE":"Adobe"},"source_url":"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194891884","content_text":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.\nLennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report on Thursday. Investor days this week include Biogen on Tuesday, Weyerhaeuser on Wednesday, and Salesforce.com on Thursday.\nThe Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s press conference with Fed chair Jerome Powell will be closely watched.\nEconomic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’ existing-home sales for August on Wednesday.\nMonday 9/20\nLennar reports third-quarter fiscal-2021 results.\nMerck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.\nThe National Association of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.\nTuesday 9/21\nAdobe, AutoZone, and FedEx release earnings.\nBiogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.\nThe Census Bureau reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.\nWednesday 9/22\nThe FOMC announces its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.\nGeneral Mills reports first-quarter fiscal-2022 results.\nBoston Scientific,Weyerhaeuser, and Yum China Holdings host their 2021 investor days.\nTheBank of Japan announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.\nThe National Association of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5% from July’s 599,000.\nThursday 9/23\nAccenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.\nSalesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.\nThe Conference Board releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.\nFriday 9/24\nKansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.","news_type":1},"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886401996,"gmtCreate":1631611320315,"gmtModify":1631884988513,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","text":"$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/886401996","isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895481324,"gmtCreate":1628765708468,"gmtModify":1631888964471,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Impressive 😄","listText":"Impressive 😄","text":"Impressive 😄","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/895481324","repostId":"1176507211","repostType":2,"repost":{"id":"1176507211","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628755698,"share":"https://www.laohu8.com/m/news/1176507211?lang=&edition=full","pubTime":"2021-08-12 16:08","market":"us","language":"en","title":"Clover Health shares rose nearly 12% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176507211","media":"Tiger Newspress","summary":"Clover Health shares rose nearly 12% in premarket trading.\nHealth care technology company Clover Hea","content":"<p>Clover Health&nbsp;shares&nbsp;rose nearly&nbsp;12% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/873c1d06cbd5a2c42b775f8b93fec480\" tg-width=\"910\" tg-height=\"651\" referrerpolicy=\"no-referrer\">Health care technology company&nbsp;<b>Clover Health</b>&nbsp;reported second-quarter earnings Wednesday afternoon.</p>\n<p>Clover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.</p>\n<p>Clover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health shares rose nearly 12% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health shares rose nearly 12% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Health&nbsp;shares&nbsp;rose nearly&nbsp;12% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/873c1d06cbd5a2c42b775f8b93fec480\" tg-width=\"910\" tg-height=\"651\" referrerpolicy=\"no-referrer\">Health care technology company&nbsp;<b>Clover Health</b>&nbsp;reported second-quarter earnings Wednesday afternoon.</p>\n<p>Clover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.</p>\n<p>Clover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176507211","content_text":"Clover Health shares rose nearly 12% in premarket trading.\nHealth care technology company Clover Health reported second-quarter earnings Wednesday afternoon.\nClover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.\nClover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807216642,"gmtCreate":1628038631786,"gmtModify":1631888964486,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807216642","repostId":"1128701390","repostType":4,"isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806890941,"gmtCreate":1627646458283,"gmtModify":1631888964499,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Hoping it will go higher😁","listText":"Hoping it will go higher😁","text":"Hoping it will go higher😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806890941","repostId":"2155158989","repostType":2,"repost":{"id":"2155158989","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627644972,"share":"https://www.laohu8.com/m/news/2155158989?lang=&edition=full","pubTime":"2021-07-30 19:36","market":"us","language":"en","title":"Exxon posts highest profit in more than a year","url":"https://stock-news.laohu8.com/highlight/detail?id=2155158989","media":"Tiger Newspress","summary":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its ","content":"<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p>\n<p>Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p>\n<p>Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p>\n<p>Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p>\n<p>Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p>\n<p>The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exxon posts highest profit in more than a year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExxon posts highest profit in more than a year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-30 19:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p>\n<p>Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p>\n<p>Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p>\n<p>Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p>\n<p>Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p>\n<p>The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155158989","content_text":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.\nExxon Mobil shares rose nearly 1% in premarket trading.\n\nOil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.\nDeep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.\nOil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.\nThe company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800206092,"gmtCreate":1627302702016,"gmtModify":1631888964510,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Yea it will go higher&nbsp;","listText":"Yea it will go higher&nbsp;","text":"Yea it will go higher","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800206092","repostId":"800203376","repostType":1,"repost":{"id":800203376,"gmtCreate":1627302521391,"gmtModify":1627313418331,"author":{"id":"3514329116425907","authorId":"3514329116425907","name":"小虎AV","avatar":"https://static.tigerbbs.com/162e12f8dcec770ec19f66f2abb0d5db","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3514329116425907","idStr":"3514329116425907"},"themes":[],"title":"Apple stock hits record high: can it go higher?","htmlText":"\n \n \n  Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>\n \n","listText":"Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>","text":"Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.$Apple(AAPL)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800203376","isVote":1,"tweetType":2,"object":{"id":"bfaa109abbbf47f287e65d43086bc18d","tweetId":"800203376","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/cd0c38dc3701925921575081150/GALbAs4cmwYA.mp4","poster":"https://static.tigerbbs.com/10fac7242dd064ef2fda4f5c609ffb73"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178984102,"gmtCreate":1626781934506,"gmtModify":1631884320896,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Hope market rebound soon","listText":"Hope market rebound soon","text":"Hope market rebound soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178984102","repostId":"145269204","repostType":1,"repost":{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141185907,"gmtCreate":1625842118809,"gmtModify":1631888964523,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"👍 nice","listText":"👍 nice","text":"👍 nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/141185907","repostId":"1113783042","repostType":4,"repost":{"id":"1113783042","pubTimestamp":1625841673,"share":"https://www.laohu8.com/m/news/1113783042?lang=&edition=full","pubTime":"2021-07-09 22:41","market":"sh","language":"en","title":"Chinese battery maker EVE to invest in lithium production","url":"https://stock-news.laohu8.com/highlight/detail?id=1113783042","media":"Reuters","summary":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium","content":"<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p>\n<p>The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p>\n<p>EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p>\n<p>The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p>\n<p>First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p>\n<p>EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p>\n<p>Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese battery maker EVE to invest in lithium production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese battery maker EVE to invest in lithium production\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 22:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"300014":"亿纬锂能"},"source_url":"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113783042","content_text":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).\nThe move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.\nEVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.\nThe two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.\nFirst-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.\nEVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.\nPrices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.","news_type":1},"isVote":1,"tweetType":1,"viewCount":97,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140747649,"gmtCreate":1625677882381,"gmtModify":1631888964538,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Finally it soar again after a few months of low&nbsp;","listText":"Finally it soar again after a few months of low&nbsp;","text":"Finally it soar again after a few months of low","images":[{"img":"https://static.tigerbbs.com/2aba790188331bc227004cc234155500","width":"1125","height":"3633"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140747649","isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":140120190,"gmtCreate":1625638951210,"gmtModify":1631888964548,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"SDNL when is&nbsp;the next surge again? Any &nbsp; &nbsp; Feedback on this stocks&nbsp;","listText":"SDNL when is&nbsp;the next surge again? Any &nbsp; &nbsp; Feedback on this stocks&nbsp;","text":"SDNL when is the next surge again? Any Feedback on this stocks","images":[{"img":"https://static.tigerbbs.com/db83977a908c8cdd0e78c34cc5e64da7","width":"1125","height":"3828"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/140120190","isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":156603367,"gmtCreate":1625215125259,"gmtModify":1631888964562,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"The future travel","listText":"The future travel","text":"The future travel","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156603367","repostId":"2148666820","repostType":4,"repost":{"id":"2148666820","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625212861,"share":"https://www.laohu8.com/m/news/2148666820?lang=&edition=full","pubTime":"2021-07-02 16:01","market":"us","language":"en","title":"Branson aims to make space trip on July 11, ahead of Bezos","url":"https://stock-news.laohu8.com/highlight/detail?id=2148666820","media":"Tiger Newspress","summary":"Virgin Galactic stock surged 37% in premarket trading.\n\nBillionaire entrepreneur Richard Branson wil","content":"<p>Virgin Galactic&nbsp;stock&nbsp;surged&nbsp;37%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ec18b866bf2b11226994a81dad0c7a78\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p>\n<p>Billionaire entrepreneur Richard Branson will travel to the edge of space on <a href=\"https://laohu8.com/S/SPCE.WS\">Virgin Galactic Holdings Inc</a>'s test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.</p>\n<p>A successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.</p>\n<p>It would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.</p>\n<p>Bezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.</p>\n<p>Reuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.</p>\n<p>The race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.</p>\n<p>\"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.</p>\n<p>Branson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.</p>\n<p>But it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.</p>\n<p>Two additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson aims to make space trip on July 11, ahead of Bezos</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson aims to make space trip on July 11, ahead of Bezos\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-02 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Virgin Galactic&nbsp;stock&nbsp;surged&nbsp;37%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ec18b866bf2b11226994a81dad0c7a78\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p>\n<p>Billionaire entrepreneur Richard Branson will travel to the edge of space on <a href=\"https://laohu8.com/S/SPCE.WS\">Virgin Galactic Holdings Inc</a>'s test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.</p>\n<p>A successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.</p>\n<p>It would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.</p>\n<p>Bezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.</p>\n<p>Reuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.</p>\n<p>The race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.</p>\n<p>\"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.</p>\n<p>Branson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.</p>\n<p>But it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.</p>\n<p>Two additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","SPCE":"维珍银河","AMZN":"亚马逊","09086":"华夏纳指-U","QNETCN":"纳斯达克中美互联网老虎指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148666820","content_text":"Virgin Galactic stock surged 37% in premarket trading.\n\nBillionaire entrepreneur Richard Branson will travel to the edge of space on Virgin Galactic Holdings Inc's test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.\nA successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.\nIt would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.\nBezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.\nReuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.\nThe race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.\n\"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.\nBranson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.\nBut it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.\nTwo additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156001375,"gmtCreate":1625184494997,"gmtModify":1631888964579,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","listText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","text":"Always read more details and find out the companies that you are buying before you stuck with all these stocks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156001375","repostId":"2148682246","repostType":4,"repost":{"id":"2148682246","pubTimestamp":1625183160,"share":"https://www.laohu8.com/m/news/2148682246?lang=&edition=full","pubTime":"2021-07-02 07:46","market":"us","language":"en","title":"After-Hours Stock Movers:BioSig,Cerence,Adtalem Global Education and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2148682246","media":"StreetInsider","summary":"After-Hours Stock Movers:\nBioSig Technologies, Inc. (Nasdaq: BSGM) 7.8% LOWER; announced that it has","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/BSGM\">BioSig Technologies, Inc.</a> (Nasdaq: BSGM) 7.8% LOWER; announced that it has commenced an underwritten public offering of its common stock.</p>\n<p>Cerence Inc (NASDAQ: CRNC) 6.9% HIGHER; will replace Adtalem Global Education Inc. (NYSE: ATGE) in the S&amp;P MidCap 400.</p>\n<p>Adtalem Global Education Inc. (NYSE: ATGE) 6.9% HIGHER; replace <a href=\"https://laohu8.com/S/BPFHW\">Boston Private Financial Holdings Inc.</a> (NASDAQ: BPFH) in the S&amp;P SmallCap 600.</p>\n<p>DHT Holdings, Inc. (NYSE: DHT) 1.9% HIGHER; purchased 3,721,841 of its own shares - equivalent to 2.2% of its outstanding shares - at an average price of $6.025 in the period from May 17, 2021 to June 7, 2021.</p>\n<p><a href=\"https://laohu8.com/S/CSSE\">Chicken Soup</a> for the Soul Entertainment, Inc. (NASDAQ: CSSE) 1.5% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers:BioSig,Cerence,Adtalem Global Education and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers:BioSig,Cerence,Adtalem Global Education and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-02 07:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18636076><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nBioSig Technologies, Inc. (Nasdaq: BSGM) 7.8% LOWER; announced that it has commenced an underwritten public offering of its common stock.\nCerence Inc (NASDAQ: CRNC) 6.9% ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18636076\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATGE":"DeVry Education Group Inc","DHT":"DHT控股","BSGM":"BioSig Technologies, Inc.","CRNC":"Cerence Inc.","CSSE":"心灵鸡汤娱乐"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18636076","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148682246","content_text":"After-Hours Stock Movers:\nBioSig Technologies, Inc. (Nasdaq: BSGM) 7.8% LOWER; announced that it has commenced an underwritten public offering of its common stock.\nCerence Inc (NASDAQ: CRNC) 6.9% HIGHER; will replace Adtalem Global Education Inc. (NYSE: ATGE) in the S&P MidCap 400.\nAdtalem Global Education Inc. (NYSE: ATGE) 6.9% HIGHER; replace Boston Private Financial Holdings Inc. (NASDAQ: BPFH) in the S&P SmallCap 600.\nDHT Holdings, Inc. (NYSE: DHT) 1.9% HIGHER; purchased 3,721,841 of its own shares - equivalent to 2.2% of its outstanding shares - at an average price of $6.025 in the period from May 17, 2021 to June 7, 2021.\nChicken Soup for the Soul Entertainment, Inc. (NASDAQ: CSSE) 1.5% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company.","news_type":1},"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151095720,"gmtCreate":1625056254660,"gmtModify":1631888964586,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Way to go","listText":"Way to go","text":"Way to go","images":[{"img":"https://static.tigerbbs.com/58f1cebd190596fc00c4e1e79a1da49d","width":"1125","height":"3558"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151095720","isVote":1,"tweetType":1,"viewCount":361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":153084347,"gmtCreate":1624986192089,"gmtModify":1631891361228,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"I don’t think it would crash. Depending which angle you are looking at .&nbsp;","listText":"I don’t think it would crash. Depending which angle you are looking at .&nbsp;","text":"I don’t think it would crash. Depending which angle you are looking at .","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153084347","repostId":"2146388793","repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://www.laohu8.com/m/news/2146388793?lang=&edition=full","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":859408655,"gmtCreate":1634718204697,"gmtModify":1634718404868,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","listText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","text":"Heard that this was old news by Politico, causing the dip of the shares.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859408655","repostId":"1174375951","repostType":4,"repost":{"id":"1174375951","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":156001375,"gmtCreate":1625184494997,"gmtModify":1631888964579,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","listText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","text":"Always read more details and find out the companies that you are buying before you stuck with all these stocks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156001375","repostId":"2148682246","repostType":4,"repost":{"id":"2148682246","pubTimestamp":1625183160,"share":"https://www.laohu8.com/m/news/2148682246?lang=&edition=full","pubTime":"2021-07-02 07:46","market":"us","language":"en","title":"After-Hours Stock Movers:BioSig,Cerence,Adtalem Global Education and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2148682246","media":"StreetInsider","summary":"After-Hours Stock Movers:\nBioSig Technologies, Inc. (Nasdaq: BSGM) 7.8% LOWER; announced that it has","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/BSGM\">BioSig Technologies, Inc.</a> (Nasdaq: BSGM) 7.8% LOWER; announced that it has commenced an underwritten public offering of its common stock.</p>\n<p>Cerence Inc (NASDAQ: CRNC) 6.9% HIGHER; will replace Adtalem Global Education Inc. (NYSE: ATGE) in the S&amp;P MidCap 400.</p>\n<p>Adtalem Global Education Inc. (NYSE: ATGE) 6.9% HIGHER; replace <a href=\"https://laohu8.com/S/BPFHW\">Boston Private Financial Holdings Inc.</a> (NASDAQ: BPFH) in the S&amp;P SmallCap 600.</p>\n<p>DHT Holdings, Inc. (NYSE: DHT) 1.9% HIGHER; purchased 3,721,841 of its own shares - equivalent to 2.2% of its outstanding shares - at an average price of $6.025 in the period from May 17, 2021 to June 7, 2021.</p>\n<p><a href=\"https://laohu8.com/S/CSSE\">Chicken Soup</a> for the Soul Entertainment, Inc. (NASDAQ: CSSE) 1.5% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers:BioSig,Cerence,Adtalem Global Education and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers:BioSig,Cerence,Adtalem Global Education and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-02 07:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18636076><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nBioSig Technologies, Inc. (Nasdaq: BSGM) 7.8% LOWER; announced that it has commenced an underwritten public offering of its common stock.\nCerence Inc (NASDAQ: CRNC) 6.9% ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18636076\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATGE":"DeVry Education Group Inc","DHT":"DHT控股","BSGM":"BioSig Technologies, Inc.","CRNC":"Cerence Inc.","CSSE":"心灵鸡汤娱乐"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18636076","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148682246","content_text":"After-Hours Stock Movers:\nBioSig Technologies, Inc. (Nasdaq: BSGM) 7.8% LOWER; announced that it has commenced an underwritten public offering of its common stock.\nCerence Inc (NASDAQ: CRNC) 6.9% HIGHER; will replace Adtalem Global Education Inc. (NYSE: ATGE) in the S&P MidCap 400.\nAdtalem Global Education Inc. (NYSE: ATGE) 6.9% HIGHER; replace Boston Private Financial Holdings Inc. (NASDAQ: BPFH) in the S&P SmallCap 600.\nDHT Holdings, Inc. (NYSE: DHT) 1.9% HIGHER; purchased 3,721,841 of its own shares - equivalent to 2.2% of its outstanding shares - at an average price of $6.025 in the period from May 17, 2021 to June 7, 2021.\nChicken Soup for the Soul Entertainment, Inc. (NASDAQ: CSSE) 1.5% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company.","news_type":1},"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141185907,"gmtCreate":1625842118809,"gmtModify":1631888964523,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"👍 nice","listText":"👍 nice","text":"👍 nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/141185907","repostId":"1113783042","repostType":4,"repost":{"id":"1113783042","pubTimestamp":1625841673,"share":"https://www.laohu8.com/m/news/1113783042?lang=&edition=full","pubTime":"2021-07-09 22:41","market":"sh","language":"en","title":"Chinese battery maker EVE to invest in lithium production","url":"https://stock-news.laohu8.com/highlight/detail?id=1113783042","media":"Reuters","summary":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium","content":"<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p>\n<p>The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p>\n<p>EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p>\n<p>The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p>\n<p>First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p>\n<p>EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p>\n<p>Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese battery maker EVE to invest in lithium production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese battery maker EVE to invest in lithium production\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 22:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"300014":"亿纬锂能"},"source_url":"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113783042","content_text":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).\nThe move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.\nEVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.\nThe two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.\nFirst-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.\nEVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.\nPrices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.","news_type":1},"isVote":1,"tweetType":1,"viewCount":97,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860844688,"gmtCreate":1632156617744,"gmtModify":1632802435367,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"😭gloomy day","listText":"😭gloomy day","text":"😭gloomy day","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860844688","repostId":"1194891884","repostType":4,"repost":{"id":"1194891884","pubTimestamp":1632091615,"share":"https://www.laohu8.com/m/news/1194891884?lang=&edition=full","pubTime":"2021-09-20 06:46","market":"us","language":"en","title":"Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1194891884","media":"Barrons","summary":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also","content":"<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p>\n<p>Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p>\n<p>The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p>\n<p>Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p>\n<p><b>Monday 9/20</b></p>\n<p>Lennar reports third-quarter fiscal-2021 results.</p>\n<p>Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p>\n<p><b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p>\n<p><b>Tuesday 9/21</b></p>\n<p>Adobe, AutoZone, and FedEx release earnings.</p>\n<p>Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p>\n<p><b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p>\n<p><b>Wednesday 9/22</b></p>\n<p><b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p>\n<p>General Mills reports first-quarter fiscal-2022 results.</p>\n<p>Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p>\n<p><b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p>\n<p><b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p>\n<p><b>Thursday 9/23</b></p>\n<p>Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p>\n<p>Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p>\n<p><b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p>\n<p><b>Friday 9/24</b></p>\n<p>Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 06:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.\n...</p>\n\n<a href=\"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","CRM":"赛富时",".DJI":"道琼斯",".SPX":"S&P 500 Index","FDX":"联邦快递",".IXIC":"NASDAQ Composite","COST":"好市多","ADBE":"Adobe"},"source_url":"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194891884","content_text":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.\nLennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report on Thursday. Investor days this week include Biogen on Tuesday, Weyerhaeuser on Wednesday, and Salesforce.com on Thursday.\nThe Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s press conference with Fed chair Jerome Powell will be closely watched.\nEconomic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’ existing-home sales for August on Wednesday.\nMonday 9/20\nLennar reports third-quarter fiscal-2021 results.\nMerck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.\nThe National Association of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.\nTuesday 9/21\nAdobe, AutoZone, and FedEx release earnings.\nBiogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.\nThe Census Bureau reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.\nWednesday 9/22\nThe FOMC announces its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.\nGeneral Mills reports first-quarter fiscal-2022 results.\nBoston Scientific,Weyerhaeuser, and Yum China Holdings host their 2021 investor days.\nTheBank of Japan announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.\nThe National Association of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5% from July’s 599,000.\nThursday 9/23\nAccenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.\nSalesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.\nThe Conference Board releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.\nFriday 9/24\nKansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.","news_type":1},"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886401996,"gmtCreate":1631611320315,"gmtModify":1631884988513,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","text":"$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/886401996","isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806890941,"gmtCreate":1627646458283,"gmtModify":1631888964499,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Hoping it will go higher😁","listText":"Hoping it will go higher😁","text":"Hoping it will go higher😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806890941","repostId":"2155158989","repostType":2,"repost":{"id":"2155158989","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627644972,"share":"https://www.laohu8.com/m/news/2155158989?lang=&edition=full","pubTime":"2021-07-30 19:36","market":"us","language":"en","title":"Exxon posts highest profit in more than a year","url":"https://stock-news.laohu8.com/highlight/detail?id=2155158989","media":"Tiger Newspress","summary":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its ","content":"<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p>\n<p>Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p>\n<p>Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p>\n<p>Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p>\n<p>Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p>\n<p>The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exxon posts highest profit in more than a year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExxon posts highest profit in more than a year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-30 19:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p>\n<p>Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p>\n<p>Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p>\n<p>Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p>\n<p>Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p>\n<p>The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155158989","content_text":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.\nExxon Mobil shares rose nearly 1% in premarket trading.\n\nOil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.\nDeep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.\nOil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.\nThe company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125760127,"gmtCreate":1624694613169,"gmtModify":1631891361256,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Yes APPLE is definitely a better buy😉","listText":"Yes APPLE is definitely a better buy😉","text":"Yes APPLE is definitely a better buy😉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125760127","repostId":"1108941456","repostType":4,"repost":{"id":"1108941456","pubTimestamp":1624664800,"share":"https://www.laohu8.com/m/news/1108941456?lang=&edition=full","pubTime":"2021-06-26 07:46","market":"us","language":"en","title":"Is Apple A Better Buy Than Other FAANG Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=1108941456","media":"seekingalpha","summary":"Apple undoubtedly is a great company, with a strong brand, excellent margins, and fundamentals, a fortress balance sheet, and massive shareholder returns.Being a great company does not mean that the stock must be a great buy. However, valuations are significantly higher than they were historically.I believe that some of the other FAANG stocks are better, while others are worse. AAPL seems like a solid, but not a spectacular investment at today's valuation.At 26-64x this year's expected net profi","content":"<p><b>Summary</b></p>\n<ul>\n <li>Apple undoubtedly is a great company, with a strong brand, excellent margins, and fundamentals, a fortress balance sheet, and massive shareholder returns.</li>\n <li>Being a great company does not mean that the stock must be a great buy. However, valuations are significantly higher than they were historically.</li>\n <li>I believe that some of the other FAANG stocks are better, while others are worse. AAPL seems like a solid, but not a spectacular investment at today's valuation.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8bb49d385ec6d3044db2f4474cbb2c57\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>MagioreStock/iStock Editorial via Getty Images</span></p>\n<p><b>Article Thesis</b></p>\n<p>Going with FAANG stocks, i.e. Facebook (FB), Apple (AAPL), Amazon (AMZN), Netflix (NFLX), and Alphabet (GOOG)(GOOGL), has been a winning trade in recent years, as those companies delivered strong gains for their owners. These companies do, however, differ quite a lot from each other in a range of metrics, including growth, valuation, and there are also differences when it comes to each company's specific risks and moat. Apple is the largest company of these in terms of profits and market capitalization, but that does not necessarily make it the best investment. In this report, we will take a look at how Apple compares versus the other FAANG members.</p>\n<p><b>Are FAANG Stocks A Good Investment?</b></p>\n<p>Looking back a couple of years, the answer is pretty clear that FAANG stocks at least<i>were</i>a good investment in the recent past:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ae2b8e2b9caf99f74c28bafc10a0a872\" tg-width=\"635\" tg-height=\"484\"><span>Data by YCharts</span></p>\n<p>With gains of 200% to 460%, these five companies easily trounced the broad market's returns over the same time, and all led to hefty gains, at least tripling an investor's money in just five years. The factors that led to these strong gains do, at least partially, still exist today. Notably, these five companies are generating compelling earnings growth, have leadership positions in the markets they address, possess strong brands that are well-received by consumers, and seem to have strong, long-term-oriented leadership teams.</p>\n<p>These factors are still in place today, which indicates that FAANG stocks could also be good investments in coming years, although investors should, even with high-quality companies, also consider a stock's valuation. Today, these companies do not look extremely cheap in most cases:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ef865eea7af4369048432a9c85d1d83\" tg-width=\"635\" tg-height=\"540\"><span>Data by YCharts</span></p>\n<p>At 26-64x this year's expected net profits, FAANG stocks can't really be called bargains, although the above-average valuations are, at least to some degree, justified due to the above-average earnings growth that these companies do generate. In any case, I doubt that investors owning FAANG stocks today will see 200%-400%+ returns over the next five years, as this seems unlikely for each of these five stocks due to the combination of current valuations and expected earnings growth. This does, however, not mean that FAANG stocks must be bad investments or underperform the market. In fact, in recent articles, I showcased that solid or even quite attractive returns can be expected from&nbsp;Facebook,Amazon, and Apple, even though the 30%-50% annual returns are likely a thing of the past - that's just mathematics, as no stock can grow at that rate forever.</p>\n<p><b>What Investors Can Expect From Apple</b></p>\n<p>Apple Inc. is not the highest-growth FAANG stock at all. Its growth has been solid but not spectacular in the recent past. This isn't a large surprise, as there is only a certain number of consumers that want to buy an iPhone or an iPad, and that amount can't grow by 50% a year for a very long time. Nevertheless, due to some market growth, some price increases, and growth from its services business, Apple should still be able to deliver sizeable revenue growth in the long run. New products such as the car project are a potential wildcard, but at least for the foreseeable future, this will not be a major profit center for the company. Apple also has a very ambitious shareholder return program, and its buybacks are an important factor for its future earnings per share growth. I believe that, overall, a high-single-digit earnings per share growth rate will be very much achievable for Apple in the long run. Combined with some multiple depression that I expect in coming years, as Apple will likely not trade at a high-20s earnings multiple forever, this gets me to a total return estimate&nbsp;in the 7% range. This is significantly less compared to what investors saw over the last couple of years, but on the other hand, 7% annual returns stemming from a strong, stable blue-chip stock such as Apple are not unattractive. I believe that some of the FAANG stocks could deliver stronger returns, primarily Alphabet and Facebook.</p>\n<p><b>Apple Versus Facebook</b></p>\n<p>Both Apple Inc. and Facebook have a great market position, but Facebook is even more dominant in its industry compared to Apple. Apple has, in the smartphone industry, a market share of around 20%, although more in the higher-end segments. Facebook, for comparison, owns four out of the top five social media networks, with Facebook, Instagram, Facebook Messenger, and WhatsApp. Clearly, FB absolutely dominates its industry. Facebook's industry is also growing quicker than the hardware IT markets that Apple serves, which is why Facebook's growth was significantly higher than Apple's growth in the recent past:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8fd8043ca75dcb2c38f5ffa427c8c0b9\" tg-width=\"635\" tg-height=\"433\"><span>Data by YCharts</span></p>\n<p>Facebook grew its revenue by well above 300% over the last five years, while Apple's revenue grew by a little less than 50%. When we look back at the total return chart at the beginning of this article and compare it to this revenue chart, we see that Apple's returns stemmed from multiple expansion to a large degree, whereas Facebook's stock actually got less expensive over the last five years. Facebook's business growth clearly outpaced its share price gains, which has made its shares less expensive. This also explains why Facebook, today, trades below the long-term median earnings multiple, whereas Apple's valuation is at the higher end of the historic range:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d3d49e0007aa77608b2992a9fef2142d\" tg-width=\"635\" tg-height=\"481\"><span>Data by YCharts</span></p>\n<p>The fact that Facebook trades at a historic discount points to a solid entry price, whereas the same can't be said about Apple. On top of that, Facebook will also grow much faster in the future - at least if the analyst community is correct:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6b16c9b3e2eac182d42686bcd8a98fc5\" tg-width=\"635\" tg-height=\"515\"><span>Data by YCharts</span></p>\n<p>While Apple is expected to see revenue growth of around 10% over the next two years, Facebook is expected to grow by 40% over the same time. Facebook's earnings per share growth estimate is also materially higher than that of Apple.</p>\n<p>To sum things up, we can say that Facebook is growing much faster, is even more dominant in its industry compared to Apple, and its shares are trading at a discount compared to the historic average, whereas Apple's shares are historically expensive. This combination makes me believe that the total return outlook for Facebook is better compared to that of Apple.</p>\n<p><b>Apple Versus Alphabet</b></p>\n<p>When we compare Apple to Alphabet, the comparison is relatively similar to what we just saw when comparing Applet to Facebook. Alphabet is a company that is growing quicker than Apple, and that can, to a large degree, be explained by its great market position and the higher market growth rate. Online advertising is a market that has been growing quicker than the tablet or smartphone market in recent years, and the same will, I believe, be true in the foreseeable future as well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6360514d097081c546a0ccacfbdc7af6\" tg-width=\"635\" tg-height=\"450\"><span>Data by YCharts</span></p>\n<p>Alphabet is forecasted to grow its revenue by more than 30% over the next two years, versus Apple's 10% growth. On top of that, at close to 20%, Alphabet is also expected to grow its earnings per share at a higher rate.</p>\n<p>Nevertheless, despite its significantly better growth forecast, Alphabet isn't a lot more expensive compared to Apple. GOOG trades at 29x forward earnings, versus AAPL's 26x forward earnings multiple. Does it make sense for GOOG to trade at a premium of just 10%, while its expected growth is one and a half times as high as that of AAPL? You be the judge, but to me, it seems like the valuation looks better at Alphabet as long as we account for the stronger growth expectations. On top of that, with a net cash position of around $120 billion, Alphabet also has one of the best balance sheets in the world. Apple, for comparison, has a somewhat<i>smaller</i>net cash position of $80 billion, although that still makes for a very strong balance sheet, of course.</p>\n<p>All in all, we can summarize that Alphabet is growing faster today, is expected to grow significantly faster in the next two years and in the long run, has an even better balance sheet and a more dominant market position, and yet it trades at an earnings multiple that is only 10% higher than that of Apple. To me, Alphabet thus looks like the more attractive pick among these two at current prices.</p>\n<p><b>Apple Versus Netflix And Amazon</b></p>\n<p>Looking at the last two remaining companies in the FAANG group, we see that, once again, AAPL is growing at a slower pace. Unless Facebook and Alphabet, however, both Netflix and Amazon are way more expensive than Apple.</p>\n<p>This huge valuation premium offsets, at least to some degree, the higher expected growth, which is why I believe that Netflix and Amazon do not really seem like much better picks compared to Apple:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ccc2536fa3cadf06639a89e0b211b9a\" tg-width=\"635\" tg-height=\"481\"><span>Data by YCharts</span></p>\n<p>AMZN and NFLX trade at PEG ratios of 1.8 and 1.9, which does not represent a clear discount compared to AAPL's valuation. On top of that, these two companies do not possess balance sheets that are as strong as that of Apple.</p>\n<p>Netflix, especially, looks significantly worse compared to the other FAANG members in terms of balance sheet strength and cash generation:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9d84f013051fbb00b6b488f5cfed66d4\" tg-width=\"635\" tg-height=\"450\"><span>Data by YCharts</span></p>\n<p>Netflix is the only FAANG member with a meaningful net debt position, and its free cash flows are equal to just 1% of its market capitalization. Netflix grows fast, but to me, it seems doubtful whether the current valuation is justified. Considering that more and more companies are pushing into the streaming market, including Disney (DIS), Amazon, and AT&amp;T(NYSE:T), more competition might hurt Netflix's margins in the future. NFLX thus seems like the worst pick among the five FAANG stocks to me, as it combines a high valuation, weak cash flows, and a somewhat uncertain competitive picture, and I think that is not fully negated by its strong growth alone.</p>\n<p>Amazon has a better market position than Netflix, a better balance sheet, and its valuation, relative to its growth, is a little lower than that of Netflix. I would rate Amazon as more or less equally attractive to Apple, although the two companies are quite different from each other in terms of growth, valuation, and shareholder returns.</p>\n<p><b>Which Is The Best FAANG Stock To Buy?</b></p>\n<p>Not every investor has the same goals, thus the answer may be different depending on what you are looking for in a stock. To me, Apple seems like a solid, but outstanding pick at current prices - the business undoubtedly is strong, the balance sheet is great, shareholder returns are hefty, but the valuation seems stretched, especially when we consider how cheap shares were in the past.</p>\n<p>Alphabet and Facebook do seem like the best FAANG picks to me today, as they combine strong growth with valuations that are only marginally higher than that of Apple. On top of that, both Alphabet and Facebook dominate their markets. Amazon is a stock that I would rate as a solid investment at today's price, so more or less in line with AAPL, whereas Netflix seems like the weakest pick among these five to me.</p>\n<p>Depending on your time horizon, appetite for risk, etc. you may disagree, however - and that's perfectly fine. I'd be glad to hear your top picks and reasoning in the comment section!</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Apple A Better Buy Than Other FAANG Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Apple A Better Buy Than Other FAANG Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-26 07:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436558-apple-better-buy-faang-stocks><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nApple undoubtedly is a great company, with a strong brand, excellent margins, and fundamentals, a fortress balance sheet, and massive shareholder returns.\nBeing a great company does not mean ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436558-apple-better-buy-faang-stocks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4436558-apple-better-buy-faang-stocks","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108941456","content_text":"Summary\n\nApple undoubtedly is a great company, with a strong brand, excellent margins, and fundamentals, a fortress balance sheet, and massive shareholder returns.\nBeing a great company does not mean that the stock must be a great buy. However, valuations are significantly higher than they were historically.\nI believe that some of the other FAANG stocks are better, while others are worse. AAPL seems like a solid, but not a spectacular investment at today's valuation.\n\nMagioreStock/iStock Editorial via Getty Images\nArticle Thesis\nGoing with FAANG stocks, i.e. Facebook (FB), Apple (AAPL), Amazon (AMZN), Netflix (NFLX), and Alphabet (GOOG)(GOOGL), has been a winning trade in recent years, as those companies delivered strong gains for their owners. These companies do, however, differ quite a lot from each other in a range of metrics, including growth, valuation, and there are also differences when it comes to each company's specific risks and moat. Apple is the largest company of these in terms of profits and market capitalization, but that does not necessarily make it the best investment. In this report, we will take a look at how Apple compares versus the other FAANG members.\nAre FAANG Stocks A Good Investment?\nLooking back a couple of years, the answer is pretty clear that FAANG stocks at leastwerea good investment in the recent past:\nData by YCharts\nWith gains of 200% to 460%, these five companies easily trounced the broad market's returns over the same time, and all led to hefty gains, at least tripling an investor's money in just five years. The factors that led to these strong gains do, at least partially, still exist today. Notably, these five companies are generating compelling earnings growth, have leadership positions in the markets they address, possess strong brands that are well-received by consumers, and seem to have strong, long-term-oriented leadership teams.\nThese factors are still in place today, which indicates that FAANG stocks could also be good investments in coming years, although investors should, even with high-quality companies, also consider a stock's valuation. Today, these companies do not look extremely cheap in most cases:\nData by YCharts\nAt 26-64x this year's expected net profits, FAANG stocks can't really be called bargains, although the above-average valuations are, at least to some degree, justified due to the above-average earnings growth that these companies do generate. In any case, I doubt that investors owning FAANG stocks today will see 200%-400%+ returns over the next five years, as this seems unlikely for each of these five stocks due to the combination of current valuations and expected earnings growth. This does, however, not mean that FAANG stocks must be bad investments or underperform the market. In fact, in recent articles, I showcased that solid or even quite attractive returns can be expected from Facebook,Amazon, and Apple, even though the 30%-50% annual returns are likely a thing of the past - that's just mathematics, as no stock can grow at that rate forever.\nWhat Investors Can Expect From Apple\nApple Inc. is not the highest-growth FAANG stock at all. Its growth has been solid but not spectacular in the recent past. This isn't a large surprise, as there is only a certain number of consumers that want to buy an iPhone or an iPad, and that amount can't grow by 50% a year for a very long time. Nevertheless, due to some market growth, some price increases, and growth from its services business, Apple should still be able to deliver sizeable revenue growth in the long run. New products such as the car project are a potential wildcard, but at least for the foreseeable future, this will not be a major profit center for the company. Apple also has a very ambitious shareholder return program, and its buybacks are an important factor for its future earnings per share growth. I believe that, overall, a high-single-digit earnings per share growth rate will be very much achievable for Apple in the long run. Combined with some multiple depression that I expect in coming years, as Apple will likely not trade at a high-20s earnings multiple forever, this gets me to a total return estimate in the 7% range. This is significantly less compared to what investors saw over the last couple of years, but on the other hand, 7% annual returns stemming from a strong, stable blue-chip stock such as Apple are not unattractive. I believe that some of the FAANG stocks could deliver stronger returns, primarily Alphabet and Facebook.\nApple Versus Facebook\nBoth Apple Inc. and Facebook have a great market position, but Facebook is even more dominant in its industry compared to Apple. Apple has, in the smartphone industry, a market share of around 20%, although more in the higher-end segments. Facebook, for comparison, owns four out of the top five social media networks, with Facebook, Instagram, Facebook Messenger, and WhatsApp. Clearly, FB absolutely dominates its industry. Facebook's industry is also growing quicker than the hardware IT markets that Apple serves, which is why Facebook's growth was significantly higher than Apple's growth in the recent past:\nData by YCharts\nFacebook grew its revenue by well above 300% over the last five years, while Apple's revenue grew by a little less than 50%. When we look back at the total return chart at the beginning of this article and compare it to this revenue chart, we see that Apple's returns stemmed from multiple expansion to a large degree, whereas Facebook's stock actually got less expensive over the last five years. Facebook's business growth clearly outpaced its share price gains, which has made its shares less expensive. This also explains why Facebook, today, trades below the long-term median earnings multiple, whereas Apple's valuation is at the higher end of the historic range:\nData by YCharts\nThe fact that Facebook trades at a historic discount points to a solid entry price, whereas the same can't be said about Apple. On top of that, Facebook will also grow much faster in the future - at least if the analyst community is correct:\nData by YCharts\nWhile Apple is expected to see revenue growth of around 10% over the next two years, Facebook is expected to grow by 40% over the same time. Facebook's earnings per share growth estimate is also materially higher than that of Apple.\nTo sum things up, we can say that Facebook is growing much faster, is even more dominant in its industry compared to Apple, and its shares are trading at a discount compared to the historic average, whereas Apple's shares are historically expensive. This combination makes me believe that the total return outlook for Facebook is better compared to that of Apple.\nApple Versus Alphabet\nWhen we compare Apple to Alphabet, the comparison is relatively similar to what we just saw when comparing Applet to Facebook. Alphabet is a company that is growing quicker than Apple, and that can, to a large degree, be explained by its great market position and the higher market growth rate. Online advertising is a market that has been growing quicker than the tablet or smartphone market in recent years, and the same will, I believe, be true in the foreseeable future as well.\nData by YCharts\nAlphabet is forecasted to grow its revenue by more than 30% over the next two years, versus Apple's 10% growth. On top of that, at close to 20%, Alphabet is also expected to grow its earnings per share at a higher rate.\nNevertheless, despite its significantly better growth forecast, Alphabet isn't a lot more expensive compared to Apple. GOOG trades at 29x forward earnings, versus AAPL's 26x forward earnings multiple. Does it make sense for GOOG to trade at a premium of just 10%, while its expected growth is one and a half times as high as that of AAPL? You be the judge, but to me, it seems like the valuation looks better at Alphabet as long as we account for the stronger growth expectations. On top of that, with a net cash position of around $120 billion, Alphabet also has one of the best balance sheets in the world. Apple, for comparison, has a somewhatsmallernet cash position of $80 billion, although that still makes for a very strong balance sheet, of course.\nAll in all, we can summarize that Alphabet is growing faster today, is expected to grow significantly faster in the next two years and in the long run, has an even better balance sheet and a more dominant market position, and yet it trades at an earnings multiple that is only 10% higher than that of Apple. To me, Alphabet thus looks like the more attractive pick among these two at current prices.\nApple Versus Netflix And Amazon\nLooking at the last two remaining companies in the FAANG group, we see that, once again, AAPL is growing at a slower pace. Unless Facebook and Alphabet, however, both Netflix and Amazon are way more expensive than Apple.\nThis huge valuation premium offsets, at least to some degree, the higher expected growth, which is why I believe that Netflix and Amazon do not really seem like much better picks compared to Apple:\nData by YCharts\nAMZN and NFLX trade at PEG ratios of 1.8 and 1.9, which does not represent a clear discount compared to AAPL's valuation. On top of that, these two companies do not possess balance sheets that are as strong as that of Apple.\nNetflix, especially, looks significantly worse compared to the other FAANG members in terms of balance sheet strength and cash generation:\nData by YCharts\nNetflix is the only FAANG member with a meaningful net debt position, and its free cash flows are equal to just 1% of its market capitalization. Netflix grows fast, but to me, it seems doubtful whether the current valuation is justified. Considering that more and more companies are pushing into the streaming market, including Disney (DIS), Amazon, and AT&T(NYSE:T), more competition might hurt Netflix's margins in the future. NFLX thus seems like the worst pick among the five FAANG stocks to me, as it combines a high valuation, weak cash flows, and a somewhat uncertain competitive picture, and I think that is not fully negated by its strong growth alone.\nAmazon has a better market position than Netflix, a better balance sheet, and its valuation, relative to its growth, is a little lower than that of Netflix. I would rate Amazon as more or less equally attractive to Apple, although the two companies are quite different from each other in terms of growth, valuation, and shareholder returns.\nWhich Is The Best FAANG Stock To Buy?\nNot every investor has the same goals, thus the answer may be different depending on what you are looking for in a stock. To me, Apple seems like a solid, but outstanding pick at current prices - the business undoubtedly is strong, the balance sheet is great, shareholder returns are hefty, but the valuation seems stretched, especially when we consider how cheap shares were in the past.\nAlphabet and Facebook do seem like the best FAANG picks to me today, as they combine strong growth with valuations that are only marginally higher than that of Apple. On top of that, both Alphabet and Facebook dominate their markets. Amazon is a stock that I would rate as a solid investment at today's price, so more or less in line with AAPL, whereas Netflix seems like the weakest pick among these five to me.\nDepending on your time horizon, appetite for risk, etc. you may disagree, however - and that's perfectly fine. I'd be glad to hear your top picks and reasoning in the comment section!","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125222641,"gmtCreate":1624676342883,"gmtModify":1631893057831,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"It is kinda&nbsp;high now to buy in ~","listText":"It is kinda&nbsp;high now to buy in ~","text":"It is kinda high now to buy in ~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/125222641","repostId":"1100072036","repostType":4,"repost":{"id":"1100072036","pubTimestamp":1624669285,"share":"https://www.laohu8.com/m/news/1100072036?lang=&edition=full","pubTime":"2021-06-26 09:01","market":"us","language":"en","title":"Tesla Stock Has Been on Fire This Week. Here Are 4 Reasons.","url":"https://stock-news.laohu8.com/highlight/detail?id=1100072036","media":"Barrons","summary":"Stock in electric-vehicle pioneer Tesla is on fire for seemingly no reason.There haven’t been any big,splashy upgrades that can explain the recent run. Shares have jumped almost 8% for the week and are on pace for their best week since April.Investors, rightly so, are wondering what’s going on. We found four reasons, outlined below.Many electric-vehicle stocks have been on a winning streak lately, beyond just Tesla. Coming into the week, shares of Chinese EV maker NIO were up 17% for the month.X","content":"<p>Stock in electric-vehicle pioneer&nbsp;Tesla&nbsp;is&nbsp;on fire&nbsp;for seemingly no reason.</p>\n<p>There haven’t been any big,splashy&nbsp;upgrades that can explain the recent run. Shares have jumped almost 8% for the week and are on pace for their best week since April.</p>\n<p>Investors, rightly so, are wondering what’s going on. We found four reasons, outlined below.</p>\n<p><b>Taking Cues From China</b></p>\n<p>Many electric-vehicle stocks have been on a winning streak lately, beyond just Tesla. Coming into the week, shares of Chinese EV maker&nbsp;NIO(NIO) were up 17% for the month.XPeng(XPEV) and&nbsp;Li Auto(LI) had gained 31% and 36%, respectively.</p>\n<p>Tesla, on the other hand, was down for the month of June coming into this week. But China is the world’s largest market for EVs, so when things are going well there, it bodes well for Tesla. It looks like some of the Chinese EV maker stocks’ shine has finally rubbed off on Tesla.</p>\n<p><b>Delivery Optimism</b></p>\n<p>The second reason is about second-quarter deliveries, after&nbsp;perceived weakness&nbsp;in Chinese delivery numbers. More recently, however, several&nbsp;reports&nbsp;have been popping up about Tesla working hard to deliver vehicles into the end of this month.</p>\n<p>“After a disaster start to the quarter for Tesla in China, the Street is reading the tea leaves as bullish for the month of June with momentum into [the second half],” Wedbush analyst&nbsp;Dan Ivestells&nbsp;Barron’s. He believes 900,000 deliveries is still possible for 2021. Wall Street is modeling about 825,000. Tesla delivered about 500,000 cars in 2020.</p>\n<p><b>Green Tidal Wave</b></p>\n<p>Ives has also written about a “green tidal wave” coming from the White House. President Joe Biden wants part of any infrastructure bill to include purchase incentives for EVs as well as charging infrastructure. A bill isn’t ready, but&nbsp;progress&nbsp;was made in Washington this week.</p>\n<p><b>Musk Tweeting, Again</b></p>\n<p>No search for the reason behind moves in Tesla stock would be complete without looking at CEO Elon Musk ‘s&nbsp;Twitter (TWTR) feed. He tweeted Friday that the updated full self-driving, or FSD, software and subscription pricing could roll out in as soon as a week.</p>\n<p>Tesla plans to offer its highest level of&nbsp;driver assistance, called full self-driving or FSD, on a subscription basis. It’s a new era for car companies, which don’t typically get to realize recurring revenue like software providers. Bulls have been waiting quite some time for the FSD subscription to arrive.</p>\n<p><b>What’s Next</b></p>\n<p>Next up for Tesla investors, after any FSD release, will be second-quarter delivery numbers and then earnings. Those data points come in July.</p>\n<p>Year to date, Tesla stock is still down about 4.8%, trailing behind comparable gains of the&nbsp;S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Has Been on Fire This Week. Here Are 4 Reasons.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Has Been on Fire This Week. Here Are 4 Reasons.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-26 09:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-stock-gains-ev-elon-musk-51624638974?mod=hp_DAY_0><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stock in electric-vehicle pioneer Tesla is on fire for seemingly no reason.\nThere haven’t been any big,splashy upgrades that can explain the recent run. Shares have jumped almost 8% for the week and ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-stock-gains-ev-elon-musk-51624638974?mod=hp_DAY_0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-gains-ev-elon-musk-51624638974?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100072036","content_text":"Stock in electric-vehicle pioneer Tesla is on fire for seemingly no reason.\nThere haven’t been any big,splashy upgrades that can explain the recent run. Shares have jumped almost 8% for the week and are on pace for their best week since April.\nInvestors, rightly so, are wondering what’s going on. We found four reasons, outlined below.\nTaking Cues From China\nMany electric-vehicle stocks have been on a winning streak lately, beyond just Tesla. Coming into the week, shares of Chinese EV maker NIO(NIO) were up 17% for the month.XPeng(XPEV) and Li Auto(LI) had gained 31% and 36%, respectively.\nTesla, on the other hand, was down for the month of June coming into this week. But China is the world’s largest market for EVs, so when things are going well there, it bodes well for Tesla. It looks like some of the Chinese EV maker stocks’ shine has finally rubbed off on Tesla.\nDelivery Optimism\nThe second reason is about second-quarter deliveries, after perceived weakness in Chinese delivery numbers. More recently, however, several reports have been popping up about Tesla working hard to deliver vehicles into the end of this month.\n“After a disaster start to the quarter for Tesla in China, the Street is reading the tea leaves as bullish for the month of June with momentum into [the second half],” Wedbush analyst Dan Ivestells Barron’s. He believes 900,000 deliveries is still possible for 2021. Wall Street is modeling about 825,000. Tesla delivered about 500,000 cars in 2020.\nGreen Tidal Wave\nIves has also written about a “green tidal wave” coming from the White House. President Joe Biden wants part of any infrastructure bill to include purchase incentives for EVs as well as charging infrastructure. A bill isn’t ready, but progress was made in Washington this week.\nMusk Tweeting, Again\nNo search for the reason behind moves in Tesla stock would be complete without looking at CEO Elon Musk ‘s Twitter (TWTR) feed. He tweeted Friday that the updated full self-driving, or FSD, software and subscription pricing could roll out in as soon as a week.\nTesla plans to offer its highest level of driver assistance, called full self-driving or FSD, on a subscription basis. It’s a new era for car companies, which don’t typically get to realize recurring revenue like software providers. Bulls have been waiting quite some time for the FSD subscription to arrive.\nWhat’s Next\nNext up for Tesla investors, after any FSD release, will be second-quarter delivery numbers and then earnings. Those data points come in July.\nYear to date, Tesla stock is still down about 4.8%, trailing behind comparable gains of the S&P 500 and Dow Jones Industrial Average.","news_type":1},"isVote":1,"tweetType":1,"viewCount":32,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":856808141,"gmtCreate":1635166163293,"gmtModify":1635166163416,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856808141","repostId":"1137044759","repostType":4,"repost":{"id":"1137044759","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635163753,"share":"https://www.laohu8.com/m/news/1137044759?lang=&edition=full","pubTime":"2021-10-25 20:09","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1137044759","media":"Tiger Newspress","summary":"U.S. futures rose slightly on Monday as traders geared for a string of earnings reports from technol","content":"<p>U.S. futures&nbsp;rose slightly&nbsp;on Monday as traders geared for a string of earnings reports from technology heavyweights including <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc., while keeping in mind inflation concerns and rising Covid-19 risks.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up&nbsp;3&nbsp;points, or 0.01%, S&amp;P 500 e-minis were up&nbsp;5.75&nbsp;points, or 0.13%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis were&nbsp;up&nbsp;44.25&nbsp;points, or 0.29%.<img src=\"https://static.tigerbbs.com/92e0a1d5cd73c51f28ccb00c8d4f071c\" tg-width=\"553\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> (PINS) – Pinterest shares tumbled 13.2% in premarket trading after&nbsp;PayPal said it was&nbsp;not pursuing an acquisition&nbsp;of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> shares jumped 6.1%.</p>\n<p><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a> (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but <a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a>’s results were hit by higher inflation and supply chain issues.</p>\n<p><a href=\"https://laohu8.com/S/QSR\">Restaurant</a> (QSR) – The restaurant operator&nbsp;reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/OTIS\">Otis Worldwide Corp</a> (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.</p>\n<p><a href=\"https://laohu8.com/S/FB\">Facebook</a> (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KNX\">Knight Transportation</a> (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.</p>\n<p><a href=\"https://laohu8.com/S/HSBC\">HSBC Holdings PLC</a> (HSBC) – HSBC&nbsp;reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.</p>\n<p><a href=\"https://laohu8.com/S/SWX\">Southwest Gas</a> (SWX) – Investor Carl Icahn is calling on <a href=\"https://laohu8.com/S/OKSB\">Southwest</a> Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company <a href=\"https://laohu8.com/S/STR\">Questar</a>. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.</p>\n<p><a href=\"https://laohu8.com/S/WHR\">Whirlpool</a> (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE),<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-25 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. futures&nbsp;rose slightly&nbsp;on Monday as traders geared for a string of earnings reports from technology heavyweights including <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc., while keeping in mind inflation concerns and rising Covid-19 risks.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up&nbsp;3&nbsp;points, or 0.01%, S&amp;P 500 e-minis were up&nbsp;5.75&nbsp;points, or 0.13%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis were&nbsp;up&nbsp;44.25&nbsp;points, or 0.29%.<img src=\"https://static.tigerbbs.com/92e0a1d5cd73c51f28ccb00c8d4f071c\" tg-width=\"553\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> (PINS) – Pinterest shares tumbled 13.2% in premarket trading after&nbsp;PayPal said it was&nbsp;not pursuing an acquisition&nbsp;of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> shares jumped 6.1%.</p>\n<p><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a> (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but <a href=\"https://laohu8.com/S/KMB\">Kimberly-Clark</a>’s results were hit by higher inflation and supply chain issues.</p>\n<p><a href=\"https://laohu8.com/S/QSR\">Restaurant</a> (QSR) – The restaurant operator&nbsp;reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/OTIS\">Otis Worldwide Corp</a> (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.</p>\n<p><a href=\"https://laohu8.com/S/FB\">Facebook</a> (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KNX\">Knight Transportation</a> (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.</p>\n<p><a href=\"https://laohu8.com/S/HSBC\">HSBC Holdings PLC</a> (HSBC) – HSBC&nbsp;reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.</p>\n<p><a href=\"https://laohu8.com/S/SWX\">Southwest Gas</a> (SWX) – Investor Carl Icahn is calling on <a href=\"https://laohu8.com/S/OKSB\">Southwest</a> Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company <a href=\"https://laohu8.com/S/STR\">Questar</a>. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.</p>\n<p><a href=\"https://laohu8.com/S/WHR\">Whirlpool</a> (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE),<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QSR":"餐饮品牌国际","PINS":"Pinterest, Inc.","SWX":"Southwest Gas Corp","WHR":"惠而浦",".DJI":"道琼斯","TSLA":"特斯拉","KNX":"Knight Transportation Inc","BNTX":"BioNTech SE","OTIS":"奥的斯","PFE":"辉瑞","HSBC":"汇丰","KMB":"金佰利"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137044759","content_text":"U.S. futures rose slightly on Monday as traders geared for a string of earnings reports from technology heavyweights including Facebook Inc., while keeping in mind inflation concerns and rising Covid-19 risks.\nAt 8:00 a.m. ET, Dow e-minis were up 3 points, or 0.01%, S&P 500 e-minis were up 5.75 points, or 0.13%, and Nasdaq 100 e-minis were up 44.25 points, or 0.29%.Stocks making the biggest moves in the premarket:\nPinterest, Inc. (PINS) – Pinterest shares tumbled 13.2% in premarket trading after PayPal said it was not pursuing an acquisition of the social media company at this time. Its statement came in response to reports that it was pursuing an acquisition of Pinterest for as much as $45 billion. PayPal shares jumped 6.1%.\nTesla Motors (TSLA) – Tesla raised prices on certain versions of its Model X and Model S cars, according to the company’s website. Additionally, car rental giant Hertz has reportedly ordered 100,000 Tesla vehicles for its fleet. Tesla shares rallied 4.3% in the premarket.\nKimberly-Clark (KMB) – The consumer products company’s stock slid 3% in premarket trading after quarterly earnings came in 3 cents a share below estimates at $1.62 per share. Revenue was slightly above forecasts, but Kimberly-Clark’s results were hit by higher inflation and supply chain issues.\nRestaurant (QSR) – The restaurant operator reported quarterly profit of $1.52 per share, 2 cents a share above estimates. Revenue was slightly below Wall Street forecasts, with Covid-19 contributing to supply chain and labor pressures for the parent of Tim Hortons, Burger King and Popeyes. The stock added 1.2% in the premarket.\nOtis Worldwide Corp (OTIS) – Otis came in 4 cents a share above estimates, with quarterly earnings of 77 cents per share. Revenue also topped analysts’ projections. The company best known for its flagship elevators also raised its full-year outlook.\nFacebook (FB) – Facebook continues to be embroiled in controversy, with a Wall Street Journal story this morning detailing internal arguments over the handling of right-leaning content. The stock fell 5% Friday, breaking a four-session win streak. Its shares dropped another 1.5% in the premarket.\nKnight Transportation (KNX) – The trucking and logistics company’s stock rose 1.5% in the premarket after UBS upgraded the stock to “buy” from “neutral.” The firm said Knight-Swift’s non-trucking business is expanding faster than it had anticipated.\nHSBC Holdings PLC (HSBC) – HSBC reported better-than-expected quarterly profit, with a 74% rise from a year earlier, and the bank also announced a $2 billion share buyback.\nSouthwest Gas (SWX) – Investor Carl Icahn is calling on Southwest Gas tofirst offer shares to existing shareholders, amid the energy producer’s plans to sell up to $1 billion in equity as part of financing to buy pipeline company Questar. Icahn – who holds a significant stake in the company – is against the deal, and is moving ahead with a tender offer to buy the shares he doesn’t already own for $75 per share.\nWhirlpool (WHR) – Whirlpool was downgraded to “underperform” from “sector perform” at RBC Capital, which cites a number of factors including the appliance maker’s loss of market share in North America. The stock slid 1.4% in premarket trading.\nPfizer (PFE),BioNTech SE (BNTX) – The Covid-19 vaccine made by Pfizer and BioNTech showed 90.7% effectiveness in children aged 5-11. Health officials say a rollout of the vaccine for kids could come as soon as early November.","news_type":1},"isVote":1,"tweetType":1,"viewCount":684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":807216642,"gmtCreate":1628038631786,"gmtModify":1631888964486,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807216642","repostId":"1128701390","repostType":4,"isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153084347,"gmtCreate":1624986192089,"gmtModify":1631891361228,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"I don’t think it would crash. Depending which angle you are looking at .&nbsp;","listText":"I don’t think it would crash. Depending which angle you are looking at .&nbsp;","text":"I don’t think it would crash. Depending which angle you are looking at .","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153084347","repostId":"2146388793","repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://www.laohu8.com/m/news/2146388793?lang=&edition=full","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125764116,"gmtCreate":1624695397935,"gmtModify":1631891361253,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Too high&nbsp;","listText":"Too high&nbsp;","text":"Too high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125764116","repostId":"2146008543","repostType":4,"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140747649,"gmtCreate":1625677882381,"gmtModify":1631888964538,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Finally it soar again after a few months of low&nbsp;","listText":"Finally it soar again after a few months of low&nbsp;","text":"Finally it soar again after a few months of low","images":[{"img":"https://static.tigerbbs.com/2aba790188331bc227004cc234155500","width":"1125","height":"3633"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140747649","isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":156603367,"gmtCreate":1625215125259,"gmtModify":1631888964562,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"The future travel","listText":"The future travel","text":"The future travel","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156603367","repostId":"2148666820","repostType":4,"repost":{"id":"2148666820","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625212861,"share":"https://www.laohu8.com/m/news/2148666820?lang=&edition=full","pubTime":"2021-07-02 16:01","market":"us","language":"en","title":"Branson aims to make space trip on July 11, ahead of Bezos","url":"https://stock-news.laohu8.com/highlight/detail?id=2148666820","media":"Tiger Newspress","summary":"Virgin Galactic stock surged 37% in premarket trading.\n\nBillionaire entrepreneur Richard Branson wil","content":"<p>Virgin Galactic&nbsp;stock&nbsp;surged&nbsp;37%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ec18b866bf2b11226994a81dad0c7a78\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p>\n<p>Billionaire entrepreneur Richard Branson will travel to the edge of space on <a href=\"https://laohu8.com/S/SPCE.WS\">Virgin Galactic Holdings Inc</a>'s test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.</p>\n<p>A successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.</p>\n<p>It would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.</p>\n<p>Bezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.</p>\n<p>Reuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.</p>\n<p>The race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.</p>\n<p>\"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.</p>\n<p>Branson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.</p>\n<p>But it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.</p>\n<p>Two additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson aims to make space trip on July 11, ahead of Bezos</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson aims to make space trip on July 11, ahead of Bezos\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-02 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Virgin Galactic&nbsp;stock&nbsp;surged&nbsp;37%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ec18b866bf2b11226994a81dad0c7a78\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p>\n<p>Billionaire entrepreneur Richard Branson will travel to the edge of space on <a href=\"https://laohu8.com/S/SPCE.WS\">Virgin Galactic Holdings Inc</a>'s test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.</p>\n<p>A successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.</p>\n<p>It would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.</p>\n<p>Bezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.</p>\n<p>Reuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.</p>\n<p>The race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.</p>\n<p>\"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.</p>\n<p>Branson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.</p>\n<p>But it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.</p>\n<p>Two additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","SPCE":"维珍银河","AMZN":"亚马逊","09086":"华夏纳指-U","QNETCN":"纳斯达克中美互联网老虎指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148666820","content_text":"Virgin Galactic stock surged 37% in premarket trading.\n\nBillionaire entrepreneur Richard Branson will travel to the edge of space on Virgin Galactic Holdings Inc's test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.\nA successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.\nIt would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.\nBezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.\nReuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.\nThe race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.\n\"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.\nBranson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.\nBut it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.\nTwo additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127784927,"gmtCreate":1624869365169,"gmtModify":1631891361235,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"😆","listText":"😆","text":"😆","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127784927","repostId":"1150627164","repostType":4,"isVote":1,"tweetType":1,"viewCount":59,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127734857,"gmtCreate":1624868509179,"gmtModify":1631891361244,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"It is another&nbsp;volatile stocks with high returns","listText":"It is another&nbsp;volatile stocks with high returns","text":"It is another volatile stocks with high returns","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127734857","repostId":"1193585957","repostType":4,"repost":{"id":"1193585957","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624867457,"share":"https://www.laohu8.com/m/news/1193585957?lang=&edition=full","pubTime":"2021-06-28 16:04","market":"us","language":"en","title":"Virgin Galactic stock surged another 8% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1193585957","media":"Tiger Newspress","summary":"Virgin Galactic stock surged another 8% in premarket trading on geting the green light from the FAA ","content":"<p>Virgin Galactic stock surged another 8% in premarket trading&nbsp;on&nbsp;geting the green light from the FAA to fly passengers to space.</p>\n<p><img src=\"https://static.tigerbbs.com/44c5e17d9158985c1507bc2372d02f3f\" tg-width=\"1302\" tg-height=\"663\"></p>\n<p>Virgin Galactic&nbsp;announced on last&nbsp;Friday that the Federal Aviation Administration granted the company the license it needs to fly passengers on future spaceflights, a key hurdle as the venture completes development testing.</p>\n<p>“The commercial license that we have had in place since 2016 remains in place, but is now cleared to allow us to carry commercial passengers when we’re ready to do so,” Virgin Galactic CEO Michael Colglazier told CNBC. “This is obviously an exciting milestone and a huge compliment to the team.”</p>\n<p>While the FAA previously gave Virgin Galactic a launch license to conduct spaceflights, the license expansion allows the company to fly what the regulator calls “spaceflight participants.” The company completed a 29 element verification and validation program for the FAA, clearing the final two FAA milestones with its most recent spaceflight test in May. Colglazier noted the two last milestones were specific to the spacecraft’s flight control systems and inertial navigation systems.</p>\n<p>Virgin Galactic’s stock rose above $40 a share this week, after a tumultuous start to the year. Shares climbed above $60 in February and then slid to a low near $15 last month before rebounding.</p>\n<p>Notably, Virgin Galactic chief astronaut trainer Beth Moses is the only non-pilot to fly on one of the company’s spaceflights. To date, five Virgin Galactic employees, including four pilots, have become FAA-recognized astronauts – as the U.S. officially views an altitude of 80 kilometers (or about 50 miles) as the boundary to space.</p>\n<p>Virgin Galactic’s spacecraft Unity is designed to hold up to six passengers along with the two pilots. The company has about 600 reservations for tickets on future flights, sold at prices between $200,000 and $250,000 each.</p>\n<p>Virgin Galactic shares soared 38.87% to $55.91&nbsp;on last&nbsp;Friday in the regular session. The company’s shares have returned 135.6% on a year-to-date basis.</p>\n<p><img src=\"https://static.tigerbbs.com/58f755be2bb3b2fcb47e5f897e49fb1d\" tg-width=\"840\" tg-height=\"470\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Virgin Galactic stock surged another 8% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVirgin Galactic stock surged another 8% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-28 16:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Virgin Galactic stock surged another 8% in premarket trading&nbsp;on&nbsp;geting the green light from the FAA to fly passengers to space.</p>\n<p><img src=\"https://static.tigerbbs.com/44c5e17d9158985c1507bc2372d02f3f\" tg-width=\"1302\" tg-height=\"663\"></p>\n<p>Virgin Galactic&nbsp;announced on last&nbsp;Friday that the Federal Aviation Administration granted the company the license it needs to fly passengers on future spaceflights, a key hurdle as the venture completes development testing.</p>\n<p>“The commercial license that we have had in place since 2016 remains in place, but is now cleared to allow us to carry commercial passengers when we’re ready to do so,” Virgin Galactic CEO Michael Colglazier told CNBC. “This is obviously an exciting milestone and a huge compliment to the team.”</p>\n<p>While the FAA previously gave Virgin Galactic a launch license to conduct spaceflights, the license expansion allows the company to fly what the regulator calls “spaceflight participants.” The company completed a 29 element verification and validation program for the FAA, clearing the final two FAA milestones with its most recent spaceflight test in May. Colglazier noted the two last milestones were specific to the spacecraft’s flight control systems and inertial navigation systems.</p>\n<p>Virgin Galactic’s stock rose above $40 a share this week, after a tumultuous start to the year. Shares climbed above $60 in February and then slid to a low near $15 last month before rebounding.</p>\n<p>Notably, Virgin Galactic chief astronaut trainer Beth Moses is the only non-pilot to fly on one of the company’s spaceflights. To date, five Virgin Galactic employees, including four pilots, have become FAA-recognized astronauts – as the U.S. officially views an altitude of 80 kilometers (or about 50 miles) as the boundary to space.</p>\n<p>Virgin Galactic’s spacecraft Unity is designed to hold up to six passengers along with the two pilots. The company has about 600 reservations for tickets on future flights, sold at prices between $200,000 and $250,000 each.</p>\n<p>Virgin Galactic shares soared 38.87% to $55.91&nbsp;on last&nbsp;Friday in the regular session. The company’s shares have returned 135.6% on a year-to-date basis.</p>\n<p><img src=\"https://static.tigerbbs.com/58f755be2bb3b2fcb47e5f897e49fb1d\" tg-width=\"840\" tg-height=\"470\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193585957","content_text":"Virgin Galactic stock surged another 8% in premarket trading on geting the green light from the FAA to fly passengers to space.\n\nVirgin Galactic announced on last Friday that the Federal Aviation Administration granted the company the license it needs to fly passengers on future spaceflights, a key hurdle as the venture completes development testing.\n“The commercial license that we have had in place since 2016 remains in place, but is now cleared to allow us to carry commercial passengers when we’re ready to do so,” Virgin Galactic CEO Michael Colglazier told CNBC. “This is obviously an exciting milestone and a huge compliment to the team.”\nWhile the FAA previously gave Virgin Galactic a launch license to conduct spaceflights, the license expansion allows the company to fly what the regulator calls “spaceflight participants.” The company completed a 29 element verification and validation program for the FAA, clearing the final two FAA milestones with its most recent spaceflight test in May. Colglazier noted the two last milestones were specific to the spacecraft’s flight control systems and inertial navigation systems.\nVirgin Galactic’s stock rose above $40 a share this week, after a tumultuous start to the year. Shares climbed above $60 in February and then slid to a low near $15 last month before rebounding.\nNotably, Virgin Galactic chief astronaut trainer Beth Moses is the only non-pilot to fly on one of the company’s spaceflights. To date, five Virgin Galactic employees, including four pilots, have become FAA-recognized astronauts – as the U.S. officially views an altitude of 80 kilometers (or about 50 miles) as the boundary to space.\nVirgin Galactic’s spacecraft Unity is designed to hold up to six passengers along with the two pilots. The company has about 600 reservations for tickets on future flights, sold at prices between $200,000 and $250,000 each.\nVirgin Galactic shares soared 38.87% to $55.91 on last Friday in the regular session. The company’s shares have returned 135.6% on a year-to-date basis.","news_type":1},"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":875712367,"gmtCreate":1637686423087,"gmtModify":1637686423087,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875712367","repostId":"1113618972","repostType":2,"repost":{"id":"1113618972","pubTimestamp":1637282847,"share":"https://www.laohu8.com/m/news/1113618972?lang=&edition=full","pubTime":"2021-11-19 08:47","market":"us","language":"en","title":"Chamath Palihapitiya says he will increase stake in Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1113618972","media":"seekingalpha","summary":"Social Capital CEO Chamath Palihapitiya said that the venture capital firm will increase its investm","content":"<p>Social Capital CEO Chamath&nbsp;Palihapitiya said that the venture capital firm will increase its investment in Clover Health Investments(NASDAQ:CLOV), according to a&nbsp;market observations letter&nbsp;he posted on his Twitter page.</p>\n<p>He cited life sciences, climate science, and alternate finance as areas \"ripe for opportunity.\"</p>\n<p>To build cash reserves and fund new investments, he is&nbsp;selling 15% of the firm's stake in SoFi Technologies(NASDAQ:SOFI).</p>\n<p>He is buying into Mitra Chem, Spectral, and Syndica.</p>\n<p>Last night, Clover Health priced a$300M public offering of common shares.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chamath Palihapitiya says he will increase stake in Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChamath Palihapitiya says he will increase stake in Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-19 08:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3772693-chamath-palihapitiya-he-will-increase-stake-in-clover-health><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Social Capital CEO Chamath Palihapitiya said that the venture capital firm will increase its investment in Clover Health Investments(NASDAQ:CLOV), according to a market observations letter he posted ...</p>\n\n<a href=\"https://seekingalpha.com/news/3772693-chamath-palihapitiya-he-will-increase-stake-in-clover-health\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://seekingalpha.com/news/3772693-chamath-palihapitiya-he-will-increase-stake-in-clover-health","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1113618972","content_text":"Social Capital CEO Chamath Palihapitiya said that the venture capital firm will increase its investment in Clover Health Investments(NASDAQ:CLOV), according to a market observations letter he posted on his Twitter page.\nHe cited life sciences, climate science, and alternate finance as areas \"ripe for opportunity.\"\nTo build cash reserves and fund new investments, he is selling 15% of the firm's stake in SoFi Technologies(NASDAQ:SOFI).\nHe is buying into Mitra Chem, Spectral, and Syndica.\nLast night, Clover Health priced a$300M public offering of common shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":895481324,"gmtCreate":1628765708468,"gmtModify":1631888964471,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Impressive 😄","listText":"Impressive 😄","text":"Impressive 😄","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/895481324","repostId":"1176507211","repostType":2,"repost":{"id":"1176507211","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628755698,"share":"https://www.laohu8.com/m/news/1176507211?lang=&edition=full","pubTime":"2021-08-12 16:08","market":"us","language":"en","title":"Clover Health shares rose nearly 12% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176507211","media":"Tiger Newspress","summary":"Clover Health shares rose nearly 12% in premarket trading.\nHealth care technology company Clover Hea","content":"<p>Clover Health&nbsp;shares&nbsp;rose nearly&nbsp;12% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/873c1d06cbd5a2c42b775f8b93fec480\" tg-width=\"910\" tg-height=\"651\" referrerpolicy=\"no-referrer\">Health care technology company&nbsp;<b>Clover Health</b>&nbsp;reported second-quarter earnings Wednesday afternoon.</p>\n<p>Clover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.</p>\n<p>Clover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health shares rose nearly 12% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health shares rose nearly 12% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Health&nbsp;shares&nbsp;rose nearly&nbsp;12% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/873c1d06cbd5a2c42b775f8b93fec480\" tg-width=\"910\" tg-height=\"651\" referrerpolicy=\"no-referrer\">Health care technology company&nbsp;<b>Clover Health</b>&nbsp;reported second-quarter earnings Wednesday afternoon.</p>\n<p>Clover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.</p>\n<p>Clover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176507211","content_text":"Clover Health shares rose nearly 12% in premarket trading.\nHealth care technology company Clover Health reported second-quarter earnings Wednesday afternoon.\nClover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.\nClover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800206092,"gmtCreate":1627302702016,"gmtModify":1631888964510,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585729847029660","idStr":"3585729847029660"},"themes":[],"htmlText":"Yea it will go higher&nbsp;","listText":"Yea it will go higher&nbsp;","text":"Yea it will go higher","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800206092","repostId":"800203376","repostType":1,"repost":{"id":800203376,"gmtCreate":1627302521391,"gmtModify":1627313418331,"author":{"id":"3514329116425907","authorId":"3514329116425907","name":"小虎AV","avatar":"https://static.tigerbbs.com/162e12f8dcec770ec19f66f2abb0d5db","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3514329116425907","idStr":"3514329116425907"},"themes":[],"title":"Apple stock hits record high: can it go higher?","htmlText":"\n \n \n  Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>\n \n","listText":"Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>","text":"Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.$Apple(AAPL)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800203376","isVote":1,"tweetType":2,"object":{"id":"bfaa109abbbf47f287e65d43086bc18d","tweetId":"800203376","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/cd0c38dc3701925921575081150/GALbAs4cmwYA.mp4","poster":"https://static.tigerbbs.com/10fac7242dd064ef2fda4f5c609ffb73"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}